December 2023 updates to the website

The website has now been updated following December's LSCMMG

The following guidelines have been added/updated:

Overactive bladder in female patients - updated

Recurrent UTI prophylactic antibiotic pathway - updated

Apomorphine shared care - update to follow

Out of area prescribing position statement - update to follow

Gender dysphoria prescribing information sheets - update to follow

Denosumab shared care - update to be published following next Clinical Effectiveness Group (CEG)

L&SC ICB recommended diabetes meters, strips and devices - update to follow 

The following medicines have been added/ updated:

Quinagolide - hyperprolactinaemia (removed)

Ibandronic acid oral - for post-menopausal osteoporosis (duplicate entry, one removed)

Warfarin - Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (updated)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Morphine Sulfate Orodispersible Tablets (Actimorph®) - severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Anastrozole - primary prevention of breast cancer

Ulipristal (Esmya) - for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed (RAG review)

Ibandronic acid injection - post-menopausal osteoporosis (RAG review)

Empagliflozin - chronic heart failure with preserved or mildly reduced ejection fraction (NICE TA929)

Tirzepatide - treating type 2 diabetes (NICE TA924)

Additional website updates:

The LSCMMG website has been updated to host Patient Group Directions (PGDs), please find more information under the 'LSC Resources' tab or here.